ES2579835T3 - Formulación de anticuerpo - Google Patents
Formulación de anticuerpo Download PDFInfo
- Publication number
- ES2579835T3 ES2579835T3 ES09764858.8T ES09764858T ES2579835T3 ES 2579835 T3 ES2579835 T3 ES 2579835T3 ES 09764858 T ES09764858 T ES 09764858T ES 2579835 T3 ES2579835 T3 ES 2579835T3
- Authority
- ES
- Spain
- Prior art keywords
- months
- dpx
- sec
- sum
- acz885
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000009472 formulation Methods 0.000 title abstract description 11
- 239000000203 mixture Substances 0.000 title abstract description 11
- 229960001838 canakinumab Drugs 0.000 abstract description 12
- 230000001105 regulatory effect Effects 0.000 abstract description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract description 2
- 229930195725 Mannitol Natural products 0.000 abstract description 2
- 239000000594 mannitol Substances 0.000 abstract description 2
- 235000010355 mannitol Nutrition 0.000 abstract description 2
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000014036 Castanea Nutrition 0.000 description 3
- 241001070941 Castanea Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012905 visible particle Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170884 | 2008-12-10 | ||
| EP08170884A EP2196476A1 (en) | 2008-12-10 | 2008-12-10 | Antibody formulation |
| PCT/EP2009/066675 WO2010066762A1 (en) | 2008-12-10 | 2009-12-09 | Antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2579835T3 true ES2579835T3 (es) | 2016-08-17 |
Family
ID=40637230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09764858.8T Active ES2579835T3 (es) | 2008-12-10 | 2009-12-09 | Formulación de anticuerpo |
| ES16162699T Active ES2900624T3 (es) | 2008-12-10 | 2009-12-09 | Formulación de anticuerpos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16162699T Active ES2900624T3 (es) | 2008-12-10 | 2009-12-09 | Formulación de anticuerpos |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20110236398A1 (enExample) |
| EP (4) | EP2196476A1 (enExample) |
| JP (5) | JP6143416B2 (enExample) |
| KR (2) | KR101762966B1 (enExample) |
| CN (3) | CN114225022A (enExample) |
| AU (1) | AU2009324371B2 (enExample) |
| BR (1) | BRPI0922730A2 (enExample) |
| CA (1) | CA2745938C (enExample) |
| CL (1) | CL2011001406A1 (enExample) |
| CO (1) | CO6361952A2 (enExample) |
| CY (2) | CY1117735T1 (enExample) |
| DK (2) | DK3072906T3 (enExample) |
| EC (1) | ECSP11011192A (enExample) |
| ES (2) | ES2579835T3 (enExample) |
| HR (2) | HRP20211899T1 (enExample) |
| HU (2) | HUE056626T2 (enExample) |
| IL (3) | IL264316B2 (enExample) |
| LT (1) | LT3072906T (enExample) |
| MA (1) | MA33023B1 (enExample) |
| MX (1) | MX2011006242A (enExample) |
| MY (2) | MY166050A (enExample) |
| NZ (1) | NZ592918A (enExample) |
| PE (1) | PE20120342A1 (enExample) |
| PL (2) | PL2376533T3 (enExample) |
| PT (2) | PT2376533T (enExample) |
| RU (2) | RU2563179C2 (enExample) |
| SI (2) | SI3072906T1 (enExample) |
| SM (1) | SMT201600222B (enExample) |
| TN (1) | TN2011000229A1 (enExample) |
| WO (1) | WO2010066762A1 (enExample) |
| ZA (1) | ZA201103362B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| PL2542257T3 (pl) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) |
| AU2011257219B2 (en) | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| PT2616090T (pt) | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro |
| CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| BR112014007852B1 (pt) | 2011-10-03 | 2021-11-03 | Moderna Therapeutics, Inc | Polinucleotídeo isolado modificado e composição farmacêutica |
| FI123630B (fi) | 2011-10-24 | 2013-08-30 | Teknologian Tutkimuskeskus Vtt | Menetelmä NFC-kalvojen valmistamiseksi alustoille |
| US20140348848A1 (en) | 2011-12-02 | 2014-11-27 | Dhananjay Kaul | Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
| NZ629204A (en) * | 2012-02-16 | 2016-09-30 | Santarus Inc | Anti-vla1 (cd49a) antibody pharmaceutical compositions |
| MX355944B (es) * | 2012-03-16 | 2018-05-07 | Regeneron Pharma | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. |
| HK1206779A1 (en) | 2012-04-02 | 2016-01-15 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| MY175388A (en) | 2012-09-20 | 2020-06-23 | Morphosys Ag | Treatment for rheumatoid arthritis |
| AU2013344796B2 (en) * | 2012-11-16 | 2016-11-10 | Novartis Ag | Use of IL-1 beta binding antibodies for treating peripheral arterial disease |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| HK1215175A1 (zh) * | 2013-03-15 | 2016-08-19 | Bayer Healthcare Llc | 抗-催乳素受體抗體製劑 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
| US20170281769A1 (en) * | 2014-09-03 | 2017-10-05 | Medimmune Limited | STABLE ANTI-IL-4Ra FORMULATION |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| MY195681A (en) * | 2015-12-07 | 2023-02-03 | Merck Patent Gmbh | Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab |
| MX2018016362A (es) * | 2016-06-27 | 2019-04-22 | Morphosys Ag | Formulaciones de anticuerpo anti-cd19. |
| JP2019521161A (ja) * | 2016-07-21 | 2019-07-25 | ノバルティス アーゲー | 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用 |
| AU2017333367A1 (en) * | 2016-09-27 | 2019-04-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| SG10201912529SA (en) | 2016-11-18 | 2020-02-27 | Astellas Pharma Inc | Novel anti-human muc1 antibody fab fragment |
| KR20200019865A (ko) * | 2017-06-22 | 2020-02-25 | 노파르티스 아게 | 암 치료에 사용하기 위한 il-1베타 결합 항체 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| BR112020004903A2 (pt) * | 2017-09-13 | 2020-09-15 | Novartis Ag | uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica |
| BR112020019065A2 (pt) * | 2018-03-23 | 2020-12-29 | AbbVie Deutschland GmbH & Co. KG | Formulações de anticorpo anti-tau aquosas estáveis |
| CA3100317A1 (en) | 2018-05-17 | 2019-11-21 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
| CN112839683B (zh) | 2018-10-10 | 2023-11-14 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| KR102735988B1 (ko) * | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| WO2022135395A1 (zh) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | 稳定的抗体制剂及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| TWI260321B (en) | 1999-09-22 | 2006-08-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| KR20080074231A (ko) | 2000-06-29 | 2008-08-12 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 및 사용 방법 |
| EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| NZ532896A (en) * | 2001-11-08 | 2007-08-31 | Pdl Biopharma Inc | Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| PL1610820T5 (pl) * | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CN101111264A (zh) * | 2005-01-28 | 2008-01-23 | 惠氏公司 | 稳定化的液体多肽制剂 |
| JP2006249083A (ja) * | 2005-03-08 | 2006-09-21 | Pharmacia & Upjohn Co Llc | 抗ｍ−ｃｓｆ抗体組成物 |
| US8858935B2 (en) * | 2005-05-19 | 2014-10-14 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| JP2009513645A (ja) | 2005-10-26 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ＩＬ−１β化合物の新規使用 |
| CN201044845Y (zh) * | 2006-10-28 | 2008-04-09 | 李开元 | 自动注射器 |
| CA2671968A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
| CA2681743A1 (en) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
-
2008
- 2008-12-10 EP EP08170884A patent/EP2196476A1/en not_active Ceased
-
2009
- 2009-12-09 PT PT97648588T patent/PT2376533T/pt unknown
- 2009-12-09 EP EP09764858.8A patent/EP2376533B1/en active Active
- 2009-12-09 DK DK16162699.9T patent/DK3072906T3/da active
- 2009-12-09 BR BRPI0922730A patent/BRPI0922730A2/pt not_active Application Discontinuation
- 2009-12-09 PL PL09764858.8T patent/PL2376533T3/pl unknown
- 2009-12-09 RU RU2011127913/15A patent/RU2563179C2/ru active
- 2009-12-09 ES ES09764858.8T patent/ES2579835T3/es active Active
- 2009-12-09 IL IL264316A patent/IL264316B2/en unknown
- 2009-12-09 CN CN202111066425.9A patent/CN114225022A/zh active Pending
- 2009-12-09 HU HUE16162699A patent/HUE056626T2/hu unknown
- 2009-12-09 HR HRP20211899TT patent/HRP20211899T1/hr unknown
- 2009-12-09 MY MYPI2014002791A patent/MY166050A/en unknown
- 2009-12-09 EP EP20197506.7A patent/EP3792282A1/en active Pending
- 2009-12-09 KR KR1020117015821A patent/KR101762966B1/ko active Active
- 2009-12-09 JP JP2011540063A patent/JP6143416B2/ja active Active
- 2009-12-09 KR KR1020177009939A patent/KR20170044211A/ko not_active Ceased
- 2009-12-09 LT LTEP16162699.9T patent/LT3072906T/lt unknown
- 2009-12-09 CA CA2745938A patent/CA2745938C/en active Active
- 2009-12-09 PL PL16162699T patent/PL3072906T3/pl unknown
- 2009-12-09 PE PE2011001179A patent/PE20120342A1/es active IP Right Grant
- 2009-12-09 EP EP16162699.9A patent/EP3072906B1/en active Active
- 2009-12-09 WO PCT/EP2009/066675 patent/WO2010066762A1/en not_active Ceased
- 2009-12-09 SI SI200932153T patent/SI3072906T1/sl unknown
- 2009-12-09 CN CN200980149644.4A patent/CN102245639B/zh active Active
- 2009-12-09 DK DK09764858.8T patent/DK2376533T3/en active
- 2009-12-09 MX MX2011006242A patent/MX2011006242A/es active IP Right Grant
- 2009-12-09 SI SI200931459A patent/SI2376533T1/sl unknown
- 2009-12-09 NZ NZ592918A patent/NZ592918A/xx unknown
- 2009-12-09 CN CN201410730219.7A patent/CN104399076B/zh active Active
- 2009-12-09 MA MA33984A patent/MA33023B1/fr unknown
- 2009-12-09 HR HRP20160754TT patent/HRP20160754T1/hr unknown
- 2009-12-09 HU HUE09764858A patent/HUE028408T2/en unknown
- 2009-12-09 US US13/133,843 patent/US20110236398A1/en not_active Abandoned
- 2009-12-09 ES ES16162699T patent/ES2900624T3/es active Active
- 2009-12-09 PT PT161626999T patent/PT3072906T/pt unknown
- 2009-12-09 MY MYPI2011002067A patent/MY157772A/en unknown
- 2009-12-09 AU AU2009324371A patent/AU2009324371B2/en active Active
- 2009-12-09 RU RU2015132431A patent/RU2745601C2/ru not_active Application Discontinuation
-
2011
- 2011-05-09 ZA ZA2011/03362A patent/ZA201103362B/en unknown
- 2011-05-10 TN TN2011000229A patent/TN2011000229A1/fr unknown
- 2011-05-16 IL IL212922A patent/IL212922B/en active IP Right Grant
- 2011-06-09 CL CL2011001406A patent/CL2011001406A1/es unknown
- 2011-06-10 CO CO11072271A patent/CO6361952A2/es not_active Application Discontinuation
- 2011-07-08 EC EC2011011192A patent/ECSP11011192A/es unknown
-
2012
- 2012-08-15 US US13/586,185 patent/US8623367B2/en active Active
-
2015
- 2015-07-01 JP JP2015132999A patent/JP2015231997A/ja not_active Withdrawn
-
2016
- 2016-06-30 CY CY20161100603T patent/CY1117735T1/el unknown
- 2016-07-11 SM SM201600222T patent/SMT201600222B/it unknown
-
2018
- 2018-05-29 JP JP2018102715A patent/JP2018168158A/ja not_active Withdrawn
-
2020
- 2020-07-16 US US16/930,475 patent/US20200384108A1/en not_active Abandoned
- 2020-08-06 JP JP2020133477A patent/JP7286595B2/ja active Active
- 2020-08-10 IL IL276622A patent/IL276622A/en unknown
-
2021
- 2021-12-07 CY CY20211101069T patent/CY1124844T1/el unknown
-
2023
- 2023-05-24 JP JP2023085464A patent/JP2023109938A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2579835T3 (es) | Formulación de anticuerpo | |
| US20190023743A1 (en) | Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution | |
| TWI332845B (en) | Aqueous sustained-release formulations of proteins | |
| Hanwright et al. | Sustained IGF-1 delivery ameliorates effects of chronic denervation and improves functional recovery after peripheral nerve injury and repair | |
| ES2308978T3 (es) | Composicion farmaceutica de eritropoyetina. | |
| ES2950570T3 (es) | Composición farmacéutica del complejo de proteína il-15 y usos de la misma | |
| CN102614134A (zh) | Vegf拮抗剂制剂 | |
| KR20170086049A (ko) | 증가된 소수성을 가지는 단백질과 단백질 콘쥬게이트 | |
| UA99830C2 (uk) | Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок | |
| CN102755649A (zh) | 药物组合物及相关方法 | |
| ES2287980T3 (es) | Composicion farmaceutica placebo liofilizable destinada a imitar un medicamento, en particular a base de proteinas o e polipeptidos. | |
| US11987608B2 (en) | Composition for accelerating cell proliferation comprising erythropoietin-derived peptide | |
| CN101351219A (zh) | 包含增效比例的干扰素γ和α的稳定的制剂 | |
| ES2452015T3 (es) | Composiciones que incluyen diferentes tipos de factores de transferencia, métodos para elaborar las composiciones, y métodos de tratamiento usando las composiciones | |
| ES2304602T3 (es) | Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1. | |
| CN114423447A (zh) | 用于延释组合物的疏水性肽盐 | |
| RU2549986C2 (ru) | Модифицированный эритропоэтин, к которому присоединена водорастворимая длинноцепочечная молекула | |
| CN102670522A (zh) | 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备 | |
| Liang et al. | Screening Natural Cholesterol Analogs to Assemble Self‐Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine | |
| Ahmed et al. | Expression of Ki67 in submandibular salivary glands of rabbits after BTX injection: histological and immunohistochemical study. | |
| US20210145941A1 (en) | Pharmaceutical compositions for treating acid sphingomyelinase deficiency | |
| ES2912162T3 (es) | Composiciones de insulina de acción rápida | |
| US20230174580A1 (en) | Molecular transport system to the central nervous system | |
| US20060178311A1 (en) | Control of lactation | |
| CN115581766A (zh) | 一种结合PD-L1/TGFβ双功能抗体融合蛋白液体制剂 |